Dainippon Pharmaceutical (TSE: 4506) announced on December 1 that its Irish licensing partner Elan Corporation has filed an application with the European Medicines Evaluation Agency for marketing authorization for “zonisamide,” an anti-epilepsy drug that is already approved for sale in Japan and the US.
